Skip to main content

Private HIV PrEP clinic in London, started and monitored properly.

Daily or event-based (2-1-1) pre-exposure prophylaxis with tenofovir/emtricitabine - BHIVA/BASHH-guided, same-week starts, and quarterly monitoring by a clinician you keep.

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private PrEP costs in London.

Indicative ranges across UK private providers. The tablets are cheap; the value is in a same-week start and a clinician who monitors you properly.

In short

£150–£350, monitored every 3 months.

Item Indicative range
Initial PrEP consultation + baseline bloods £250–£400
Quarterly follow-up + monitoring bloods £150–£250
Full 4-visit annual plan £600–£1,000
Event-based (2-1-1) counselling add-on £80–£150
Generic tenofovir/emtricitabine (30 tablets, private) £25–£60
Consultation only £150–£300

Prices vary by clinic, by clinician and by whether you use a private script or an NHS supply for the tablets themselves.

The problem

The right regimen, started this week, monitored properly.

PrEP is one of the most effective preventive interventions in medicine - when it is started on the right regimen, at the right time, and with quarterly monitoring that actually happens.

  • Waiting weeks for an NHS slot?

    NHS PrEP is free and excellent, but a first appointment can take weeks in busy boroughs. We can start you this week and hand back to NHS monitoring later.

  • Confused between daily and 2-1-1?

    Daily suits most; event-based 2-1-1 is BHIVA-approved for cis MSM only. We spell out the trade-offs so you pick the one that fits your life.

  • Worried about privacy at work or GP?

    No letters home, no notes to your GP unless you ask. Everything stays inside the clinic - including your monitoring bloods.

When it helps

When PrEP is the right tool.

The indications we see most, plus the red flag that means an urgent HIV test and PEP today - not a PrEP appointment next week.

  • MSM with recent condomless sex

    Men who have sex with men reporting condomless anal sex in the past 6 months, or a recent bacterial STI, meet BHIVA/BASHH criteria for PrEP.

  • Partner living with HIV (detectable)

    A sero-different relationship where the partner is not yet on suppressive treatment, or viral load is not confirmed undetectable.

  • Sex workers

    People selling or exchanging sex with variable condom use, especially where partner HIV status is unknown.

  • Injecting drug use

    Anyone injecting drugs and sharing equipment, or sharing chemsex injecting kit, benefits from a formal PrEP discussion.

  • Chemsex participants

    Use of mephedrone, GHB/GBL or crystal meth during sex materially raises HIV acquisition risk - PrEP plus harm-reduction support.

  • Planning pregnancy, sero-different

    When the partner living with HIV is not confirmed undetectable, PrEP for the HIV-negative partner is a safe option through conception.

  • Travel to high-prevalence settings

    Extended stays in regions with high HIV prevalence and anticipated condomless sex - PrEP started before travel, monitored on return.

  • Red flag: acute HIV symptoms

    Fever, sore throat, rash and lymph nodes days after an exposure is not a PrEP conversation - it needs urgent HIV testing and PEP, today.

Regimens and monitoring

PrEP is one drug, but not one regimen.

The dosing options, and the baseline plus quarterly checks that keep PrEP safe over months and years.

  • Daily PrEP

    One tablet of tenofovir/emtricitabine, every day. The simplest, most forgiving regimen - protective for vaginal, anal and injecting exposures, and the only option for people with a vagina.

  • Event-based (2-1-1) dosing

    BHIVA-approved for cis MSM. Two tablets 2–24 hours before sex, one at 24 hours, one at 48 hours. Useful for infrequent, plannable exposures - not for vaginal sex.

  • Initial 4th-gen HIV Ab/Ag test

    A combined antibody/antigen test at baseline, and at every quarterly review. Rules out established or recent HIV before a script is issued.

  • Renal function (eGFR/creatinine)

    Tenofovir is renally cleared. Baseline and quarterly eGFR keeps a lookout for the small proportion who develop a rise in creatinine on treatment.

  • Hepatitis B screen and vaccination

    Hepatitis B status is checked before starting - tenofovir also treats hep B, so stopping abruptly can flare it. Non-immune patients are offered vaccination.

  • STI screen quarterly

    HIV is one risk of unprotected sex - chlamydia, gonorrhoea, syphilis and hepatitis C are the others. Full 4-site screening every 3 months while on PrEP.

  • Adherence and side-effect check

    A short conversation at each visit on missed doses, timing around sex, GI upset in the first month, and anything getting in the way of consistent use.

  • When to stop or step down

    Risk changes. If a relationship becomes monogamous with a confirmed-undetectable partner, or exposures stop, we plan a safe stop - including hep B monitoring after cessation.

Safety and monitoring

What to plan around - honestly.

PrEP is one of the most-studied preventive medicines of the last decade. The things worth planning are baseline HIV testing, kidney checks, hepatitis B status and continued STI screening.

  • Undiagnosed acute HIV risk

    Starting PrEP during an unrecognised seroconversion can promote drug resistance. A 4th-generation HIV test at baseline - and at every quarter - is non-negotiable.

  • Renal function

    Tenofovir raises creatinine in a minority. eGFR is checked at baseline and quarterly; dose adjustment or a switch is discussed if it drops meaningfully.

  • Bone density long-term

    Small reductions in bone mineral density are seen with long-term tenofovir. Reversible on stopping and rarely clinically significant, but worth naming.

  • Hepatitis B flare on stopping

    In anyone with chronic hepatitis B, stopping tenofovir can cause a hepatitis flare. Status is checked before starting and monitored if PrEP is paused.

  • STI displacement of condom use

    PrEP prevents HIV, not chlamydia, gonorrhoea, syphilis or hep C. Quarterly full STI screens are part of the plan, not an optional add-on.

  • Drug interactions

    Interactions are few - mostly other nephrotoxic drugs, some gender-affirming hormones, and certain hepatitis C regimens. Reviewed at every visit.

  • Adherence gaps

    Missed doses matter more with event-based than daily dosing.

  • Side effects in the first four weeks

    Nausea, mild headache and loose stools in around 1 in 10 in the first month - almost always self-limiting. Worth expecting rather than being surprised by.

Reading your clinic letter

Your PrEP letter in four parts. Read the last one first.

Whether you are on daily or event-based dosing, the letter the clinician sends after each visit keeps to the same shape.

A UK sexual-health clinician reviewing a patient’s PrEP monitoring results

A quiet reminder

Clinical language is precise and can read coldly - we translate it for you.

If you would like us to walk you through the letter before your next review, just ask.

  1. 01 Header

    Indication and eligibility

    Why PrEP was started - the exposure profile, partner status, prior PEP or STI history - and confirmation of a negative baseline HIV test.

  2. 02 Technique

    Regimen and technique of dosing

    Whether daily or event-based (2-1-1), the exact tablets prescribed, the loading dose if event-based, and what to do around planned or unplanned sex.

  3. 03 Findings

    Bloods and screen results

    HIV Ab/Ag, renal function (eGFR/creatinine), hepatitis B status, and the full STI screen - chlamydia, gonorrhoea, syphilis, hepatitis C - with any positives flagged.

  4. 04 Impression

    Plan and next review

    Read this first: your continuing dose, when the next quarterly bloods are due, any interactions flagged, and the plan if you want to stop or step down.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Insurance cover for PrEP itself is limited on most UK policies as it is a preventive prescription, but consultations and monitoring bloods are often reimbursable.

Frequently asked

Everything we get asked about HIV PrEP.

Quick answers on eligibility, daily versus 2-1-1, NHS versus private, safety, cost and missed doses.

  • Who should actually consider PrEP?

    BHIVA/BASHH criteria cover men who have sex with men reporting condomless anal sex in the past six months or a recent bacterial STI, sero-different couples where the partner is not confirmed undetectable, people who share injecting equipment, sex workers, and anyone with a foreseeable exposure such as a partner’s treatment interruption or travel to a high-prevalence setting. If you are not sure whether you qualify, ask - the triage is short.

  • What is the difference between daily PrEP and event-based (2-1-1)?

    Daily PrEP is one tablet every day and works for vaginal, anal and injecting exposures. Event-based 2-1-1 is BHIVA-approved for cis men who have sex with men only: two tablets 2–24 hours before sex, one at 24 hours after the first dose, one at 48 hours. It suits infrequent, plannable exposures. It is not recommended for vaginal sex or for trans women on oestrogens.

  • Can I get PrEP on the NHS, and why go private?

    Yes - PrEP is available NHS-funded through specialist sexual-health clinics across England, Scotland, Wales and Northern Ireland. Access is genuinely free, but waits for a first slot and for monitoring appointments have lengthened in many areas. The private route offers a same-week start, continuity of clinician and a proper conversation about event-based dosing. The drug itself is inexpensive, so many patients start privately and move to NHS monitoring later.

  • How safe is long-term PrEP - kidneys and bones?

    Tenofovir/emtricitabine has a strong safety record over more than a decade. A minority see a small rise in creatinine and a small drop in bone mineral density - both usually reversible on stopping. Baseline and quarterly eGFR is standard, and we adjust or switch if there is a meaningful change. For most people, the numbers stay well within safe limits.

  • How much does private PrEP actually cost?

    The tablets themselves are inexpensive - generic tenofovir/emtricitabine is £25–£60 for a month’s supply on private script. All in, most patients budget £150–£350 per quarter.

Related tests

Looking for something else?